Table 3.
Major studies evaluating the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on obesity in patients with polycystic ovary syndrome.
| Reference | SGLT-2 Inhibitor | n | Follow-Up (Weeks) |
Baseline Body Mass Index (kg/m2) | Lifestyle Intervention | Metformin Treatment | Main Results |
|---|---|---|---|---|---|---|---|
| [74] | Empagliflozin 25 mg/day | 39 | 12 | 37.9 | No | Comparator arm | Greater reduction in body weight than metformin |
| [75] | Canagliflozin 100 mg/day | 41 | 12 | 30.2 | No | Comparator arm | Canagliflozin/metformin induced similar reductions in body weight with metformin |
| [77] | Dapagliflozin 10 mg/day | 92 | 24 | 38.5 | Diet and exercise | Comparator arm | Dapagliflozin/exenatide induced similar body weight loss with phentermine/topiramate and greater than exenatide, dapagliflozin and dapaglifozin/metformin |